As prescriptions for the appetite-suppressing drug Ozempic soar worldwide, scientists are uncovering both its advantages and limitations in real-time. Originally developed for diabetes management, Ozempic is now showing promise for heart health and potentially boosting kidney function.
Ozempic users had a 24% lower risk of significant kidney events
A large international trial funded by Novo Nordisk, Ozempic’s manufacturer, indicates that the drug benefits kidneys at a lower dose than typically used for diabetes or weight loss. The study involved over 3,500 participants with type 2 diabetes and chronic kidney disease, spanning 28 countries. These conditions, combined, elevate the risk of kidney failure and cardiovascular events.
From June 2019 to May 2021, half the participants received weekly low doses of semaglutide, Ozempic’s active ingredient, while the other half received a placebo. Results showed that those on Ozempic experienced slower kidney function decline, a reduced risk of renal failure, lower systolic blood pressure, and weight loss compared to the placebo group.
After 3.4 years, Ozempic users had a 24% lower risk of significant kidney events, an 18% lower chance of major cardiovascular events, and a 20% reduced risk of death from any cause. Initial research, both commercial and independent, suggests Ozempic may enhance kidney function, which is crucial for waste elimination and blood pressure regulation.
These benefits may stem from Ozempic’s indirect effects, such as lowering blood pressure, body weight, and blood glucose levels, which reduce kidney strain. However, these are currently hypotheses. Further research is needed to understand how semaglutide and similar drugs affect various organs.
Ongoing studies are exploring whether these drugs benefit chronic kidney disease patients generally or specifically those with diabetic kidney disease.
